Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

6.420 -0.030 (-0.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
28 29 Next >
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Atai Life Sciences' Depression Candidate Faces Trial Setback, Shares Nosedive
 
Via Benzinga
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From January 5, 2023
 
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 2, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 3, 2023
 
Via Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 30, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 29, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 28, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 27, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 26, 2022
 
Via Benzinga
Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More
Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries 
Via Benzinga
Largest Psychedelic Stocks -7.6% This Week; Now -21.7% This Month
Highlighting the performance of the six stocks in our Psychedelic Drug Stocks Index, which are researching the treatment of mental illnesses using 10 different psychedelic substances. 
Via Talk Markets
Cannabis Category Performances Ranged From +0.5% To -17% Last Week
The 5 categories in the cannabis sector perform quite differently week-to-week and last week was no exception. Below is a summary of each category's performance last week, in descending order, since... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 23, 2022
 
Via Benzinga
Dow Rises 150 Points; Mission Produce Shares Slide
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 150 points on Friday. 
Via Benzinga
Cybin, ATAI Life Sciences Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 21, 2022
 
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Dow Surges Over 100 Points; Crude Oil Rises Sharply
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 100 points on Friday. 
Via Benzinga
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
From atai Life Sciences
Via GlobeNewswire
ATAI Life Sciences's Return On Capital Employed Insights
 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 19, 2022
 
Via Benzinga
3 (Risky) Tricks for Finding Monster Growth Stocks
Stocks with big upside potential often have significant risks, too. 
Via The Motley Fool
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.